Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.

The pharmacogenomics journal - 1 Jan 2000

Risner M E, Saunders A M, Altman J F B, Ormandy G C, Craft S, Foley I M, Zvartau-Hind M E, Hosford D A, Roses A D

Abstract excerpt

Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the inte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein E4
Share to Apolipoproteins E
Share to Cognition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Hypoglycemic Agents

Share to Pharmacogenetics

Share to Rosiglitazone

Share to Thiazolidinediones

Source

Identifiers

PMID: 16446752
DOI: 10.1038/sj.tpj.6500369

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16446752-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.PMID 16446752Read ↗

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.Semantic proximity Read ↗

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).Semantic proximity Read ↗

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseaseSemantic proximity Read ↗

Metrifonate treatment of AD: influence of APOE genotype.Semantic proximity Read ↗

Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.Semantic proximity Read ↗

APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.Semantic proximity Read ↗

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.Semantic proximity Read ↗

Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.Semantic proximity Read ↗

Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.